Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of metabolic pathways contributing to ER+ breast cancer disparities using a machine-learning pipeline.
Santaliz-Casiano A, Mehta D, Danciu OC, Patel H, Banks L, Zaidi A, Buckley J, Rauscher GH, Schulte L, Weller LR, Taiym D, Liko-Hazizi E, Pulliam N, Friedewald SM, Khan S, Kim JJ, Gradishar W, Hegerty S, Frasor J, Hoskins KF, Madak-Erdogan Z. Santaliz-Casiano A, et al. Among authors: gradishar w. Sci Rep. 2023 Jul 26;13(1):12136. doi: 10.1038/s41598-023-39215-1. Sci Rep. 2023. PMID: 37495653 Free PMC article.
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).
Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W. Kaklamani VG, et al. Among authors: gradishar w. Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26. Breast Cancer Res Treat. 2015. PMID: 26006067 Clinical Trial.
Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate.
Lee O, Sullivan ME, Xu Y, Rogers C, Muzzio M, Helenowski I, Shidfar A, Zeng Z, Singhal H, Jovanovic B, Hansen N, Bethke KP, Gann PH, Gradishar W, Kim JJ, Clare SE, Khan SA. Lee O, et al. Among authors: gradishar w. Clin Cancer Res. 2020 Jan 1;26(1):25-34. doi: 10.1158/1078-0432.CCR-19-0443. Epub 2019 Sep 30. Clin Cancer Res. 2020. PMID: 31570566 Clinical Trial.
Daily Physical Activity and Symptom Reporting in Breast Cancer Patients Undergoing Chemotherapy: An Intensive Longitudinal Examination.
Phillips SM, Welch WA, Fanning J, Santa-Maria CA, Gavin KL, Auster-Gussman LA, Solk P, Lu M, Cullather E, Khan SA, Kulkarni SA, Gradishar W, Siddique J. Phillips SM, et al. Among authors: gradishar w. Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2608-2616. doi: 10.1158/1055-9965.EPI-20-0659. Epub 2020 Sep 29. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 32994340 Free PMC article.
Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non-Safety-Net Centers.
Trosman JR, Weldon CB, Rapkin BD, Benson AB 3rd, Makower DF, Liang SY, Kulkarni SA, Perez CB, Lo SS, Krueger EA, Throckmorton AD, Gallagher C, Hoskins K, Schaeffer CM, Van Horn J, Schapira L, Ravelo A, Yu E, Gradishar WJ. Trosman JR, et al. JCO Oncol Pract. 2021 Aug;17(8):e1202-e1214. doi: 10.1200/OP.21.00161. JCO Oncol Pract. 2021. PMID: 34375560
313 results